References

farmaec

FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology

ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология

2070-49092070-4933

IRBIS LLC

10.17749/2070-4909/farmakoekonomika.2024.249

farmaec-1037

Research Article

REVIEW ARTICLES

ОБЗОРНЫЕ ПУБЛИКАЦИИ

Cystatin C: diagnostic and prognostic value in acute kidney injury

Цистатин С: диагностико-прогностическая ценность при остром повреждении почек

https://orcid.org/0000-0002-0459-0488

Корабельников

Д. И.

Korabelnikov

D. I.

Корабельников Даниил Иванович – к.м.н., доцент, заведующий кафедрой внутренних болезней с курсами семейной медицины, функциональной диагностики, инфекционных болезней, ректор

Scopus Author ID: 7801382184

ул. 2-я Брестская, д. 5, Москва 123056

Daniil I. Korabelnikov – MD, PhD, Associate Professor, Chief of Chair of Internal Diseases with Courses in Family Medicine, Functional Diagnostics, Infectious Diseases, Rector

Scopus Author ID: 7801382184

5 Brestskaya Str., Moscow 123056

https://orcid.org/0000-0002-0483-1050

Магомедалиев

М. О.

Magomedaliev

M. O.

Магомедалиев Магомедали Омарасхабович – ассистент кафедры хирургических болезней с курсами эндоскопии, анестезиологии и реаниматологии, акушерства и гинекологии АНО ДПО «Московский медико-социальный институт им. Ф.П. Гааза», начальник отделения реанимации и интенсивной терапии центра анестезиологии, реанимации и интенсивной терапии ФГКУ «1586 Военный клинический госпиталь»

Scopus Author ID: 58284748000

ул. 2-я Брестская, д. 5, Москва 123056

ул. Маштакова, д. 4, Подольск 142110

Magomedali O. Magomedaliev – Assistant Professor, Chair of Surgical Diseases with Courses in Endoscopy, Anesthesiology and Intensive Care, Obstetrics and Gynecology, Moscow Haass Medical Social Institute (Moscow, Russia); Head of the Intensive Care Unit, Center of Anesthesiology, Resuscitation and Intensive Care, 1586 Military Clinical Hospital

Scopus Author ID: 58284748000

5 Brestskaya Str., Moscow 123056

4 Mashtakov Str., Podolsk 142110

magomedalim@mail.ru

Автономная некоммерческая организация дополнительного профессионального образования «Московский медико-социальный институт им. Ф.П. Гааза»РоссияMoscow Haass Medical Social InstituteRussian Federation

Автономная некоммерческая организация дополнительного профессионального образования «Московский медико-социальный институт им. Ф.П. Гааза»; Федеральное государственное казенное учреждение «1586 Военный клинический госпиталь» Министерства обороны Российской ФедерацииРоссияMoscow Haass Medical Social Institute; 1586 Military Clinical HospitalRussian Federation

2024

04082024

172220231

2024

Корабельников Д.И., Магомедалиев М.О.

Korabelnikov D.I., Magomedaliev M.O.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.pharmacoeconomics.ru/jour/article/view/1037

Acute kidney injury (AKI) is a life-threatening condition that occupies one of the leading places in the structure of mortality in intensive care units. AKI markers common in clinical practice are characterized by a number of disadvantages: serum creatinine – late response to damage to the kidney tubules, an increase in damage to more than 50% of nephrons; urine volume – limited diagnostic value and overdiagnosis of AKI in dehydration, the impossibility of assessing on the basis of a single measurement, as well as the need for regular and frequent dynamic monitoring. The review considers the diagnostic and prognostic possibilities of cystatin C (CysC) in AKI. The results of 55 researches were analyzed. The influence of a number of physiological conditions and non-renal diseases on blood serum and urinary CysC levels were shown. These indicators proved to be highly sensitive and specific biomarkers for AKI diagnosis and prognosis, allowing the specialists to verify renal dysfunction at an early stage of development, ahead of structural changes, and thereby to timely correct treatment, including withdrawal of nephrotoxic drugs and initiation of nephroprotection therapy.

Острое повреждение почек (ОПП) – жизнеугрожающее состояние, занимающее одно из лидирующих позиций в структуре летальности в отделениях реанимации. Распространенные в клинической практике маркеры ОПП характеризуются целым рядом недостатков: креатинин сыворотки крови – позднее реагирование на повреждение канальцев почек, повышение при повреждении более 50% нефронов; объем мочи – ограничение диагностической ценности и гипердиагностика ОПП при дегидратации, невозможность оценки на основании однократного измерения, а также необходимость в регулярном и частом динамическом контроле. В обзоре рассмотрены диагностические и прогностические возможности цистатина С (англ. cystatin C, CysC) при ОПП. Проанализированы результаты 55 исследовательских работ. Показано влияние ряда физиологических состояний и непочечных заболеваний на уровни CysC в сыворотке крови и моче. Эти показатели зарекомендовали себя как высокочувствительные и специфичные биомаркеры диагностики и прогноза ОПП, позволяющие верифицировать почечную дисфункцию на ранней стадии развития, опережая структурные изменения и тем самым позволяя своевременно корректировать лечение, в т.ч. отменять нефротоксичные препараты и инициировать нефропротективную терапию.

острое повреждение почекОППбиомаркерыцистатин С

Acute kidney injuryAKIbiomarkerscystatin C

References1

Waikar S.S., Bonventre J.V. Creatinine kinetics and the definition of acute kidney injury. J Am Soc Nephrol. 2009; 20 (3): 672–9. https://doi.org/10.1681/ASN.2008070669.

Корабельников Д.И., Магомедалиев М.О. Современные биомаркеры острого повреждения почек. ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология. 2023; 16 (1): 87–104. https://doi.org/10.17749/2070-4909/farmakoekonomika.2023.171.

Korabelnikov D.I., Magomedaliev M.O. Modern biomarkers of acute kidney injury. FARMAKOEKONOMIKA. Sovremennaya farmako-ekonomika i farmakoepidemiologiya / FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2023; 16 (1): 87–104 (in Russ.). https://doi.org/10.17749/2070-4909/farmakoekonomika.2023.171.

Klein S.J., Lehner G.F., Forni L.G., Joannidis M. Oliguria in critically ill patients: a narrative review. J Nephrol. 2018; 31 (6): 855–62. https://doi.org/10.1007/s40620-018-0539-6.

Ahuja S.S., Castillo B. (Eds.) Kidney biomarkers. Clinical aspects and laboratory determination. Academic Press; 2020: 342 pp. https://doi.org/10.1016/B978-0-12-815923-1.09997-1.

Herget-Rosenthal S., Marggraf G., Hüsing J., et al. Early detection of acute renal failure by serum cystatin C. Kidney Int. 2004; 66 (3): 1115– 22. https://doi.org/10.1111/j.1523-1755.2004.00861.x.

Ling Q., Xu X., Li J.J., et al. Alternative definition of acute kidney injury following liver transplantation: based on serum creatinine and cystatin C levels. Transplant Proc. 2007; 39 (10): 3257–60. https://doi.org/10.1016/j.transproceed.2007.03.107.

Kato K., Sato N., Yamamoto T., et al. Valuable markers for contrastinduced nephropathy in patients undergoing cardiac catheterization. Circ J. 2008; 72 (9): 1499–505. https://doi.org/10.1253/circj.CJ-07-1006.

Koyner J.L., Bennett M.R., Worcester E.M., et al. Urinary cystatin C as an early biomarker of acute kidney injury following adult cardiothoracic surgery. Kidney Int. 2008; 74 (8): 1059–69. https://doi.org/10.1038/ki.2008.341.

Haase M., Bellomo R., Devarajan P., et al. Novel biomarkers early predict the severity of acute kidney injury after cardiac surgery in adults. Ann Thorac Surg. 2009; 88 (1): 124–30. https://doi.org/10.1016/j.athoracsur.2009.04.023.

Haase-Fielitz A., Bellomo R., Devarajan P., et al. Novel and conventional serum biomarkers predicting acute kidney injury in adult cardiac surgery – a prospective cohort study. Crit Care Med. 2009; 37 (2): 553–60. https://doi.org/10.1097/CCM.0b013e318195846e.

Soto K., Coelho S., Rodrigues B., et al. Cystatin C as a marker of acute kidney injury in the emergency department. Clin J Am Soc Nephrol. 2010; 5 (10): 1745–54. https://doi.org/10.2215/CJN.00690110.

Nejat M., Pickering J.W., Walker R.J., Endre Z.H. Rapid detection of acute kidney injury by plasma cystatin C in the intensive care unit. Nephrol Dial Transplant. 2010; 25 (10): 3283–9. https://doi.org/10.1093/ndt/gfq176.

Briguori C., Visconti G., Rivera N.V., et al. Cystatin C and contrastinduced acute kidney injury. Circulation. 2010; 121 (19): 2117–22. https://doi.org/10.1161/CIRCULATIONAHA.109.919639.

Chen T., Chang C.H., Lin C.Y., et al. Acute kidney injury biomarkers for patients in a coronary care unit: a prospective cohort study. PLoS One. 2012; 7 (2): e32328. https://doi.org/10.1371/journal.pone.0032328.

Hsiao P., Hsieh C.A., Yeh C.F., et al. Early prediction of acute kidney injury in patients with acute myocardial injury. J Crit Care. 2012; 27 (5): 525.e1–7. https://doi.org/10.1016/j.jcrc.2012.05.003.

Liu X., Wang Z.J., Yang Q., et al. Plasma neutrophil-gelatinase-associated lipocalin and cystatin C could early diagnose contrast-induced acute kidney injury in patients with renal insufficiency undergoing an elective percutaneous coronary intervention. Chin Med J. 2012; 125 (6): 1051–6.

Kokkoris S., Parisi M., Ioannidou S., et al. Combination of renal biomarkers predicts acute kidney injury in critically ill adults. Ren Fail. 2012; 34 (9): 1100–8. https://doi.org/10.3109/0886022X.2012.713279.

Aydoğdu M., Gürsel G., Sancak B., et al. The use of plasma and urine neutrophil gelatinase associated lipocalin (NGAL) and cystatin C in early diagnosis of septic acute kidney injury in critically ill patients. Dis Markers. 2013; 34 (4): 237–46. https://doi.org/10.3233/DMA-130966.

Villa P., Jiménez M., Soriano M.C., et al. Serum cystatin C concentration as a marker of acute renal dysfunction in critically ill patients. Crit Care. 2005; 9 (2): 139–43. https://doi.org/10.1186/cc3044.

Martensson J., Martling C.R., Oldner A., Bell M. Impact of sepsis on levels of plasma cystatin C in AKI and non-AKI patients. Nephrol Dial Transplant. 2012; 27 (2): 576–81. https://doi.org/10.1093/ndt/gfr358.

Wan Z.H., Wang J.J., You S.L. Cystatin C is a biomarker for predicting acute kidney injury in patients with acute-on-chronic liver failure. World J Gastroenterol. 2013; 19 (48): 9432–8. https://doi.org/10.3748/wjg.v19.i48.9432.

Ghonemy T., Amro G. Plasma neutrophil gelatinase-associated lipocalin (NGAL) and plasma cystatin C (CysC) as biomarker of acute kidney injury after cardiac surgery. Saudi J Kidney Dis Transplant. 2014; 25 (3): 582–8. https://doi.org/10.4103/1319-2442.132194.

Alharazy S.M., Kong N., Saidin R., et al. Serum neutrophil gelatinase-associated lipocalin and cystatin C are early biomarkers of contrast-induced nephropathy after coronary angiography in patients with chronic kidney disease. Angiology. 2014; 65 (5): 436–42. https://doi.org/10.1177/0003319713483918.

Yang H., Yim H., Cho Y.S., et al. Assessment of biochemical markers in the early post-burn period for predicting acute kidney injury and mortality in patients with major burn injury: comparison of serum creatinine, serum cystatin-C, plasma and urine neutrophil gelatinase-associated lipocain. Crit Care. 2014; 18 (4): R151. https://doi.org/10.1186/cc13989.

Ortuño-Andériz F., Cabello-Clotet N., Vidart-Simón N., et al. Cystatin C as an early marker of acute kidney injury in septic shock. Rev Clin Esp. 2015; 215 (2): 83–90. https://doi.org/10.1016/j.rce.2014.09.010.

Prowle J.R., Calzavacca P., Licari E., et al. Combination of biomarkers for diagnosis of acute kidney injury after cardiopulmonary bypass. Renal Fail. 2015; 37 (3): 408–16. https://doi.org/10.3109/0886022X.2014.1001303.

Arun O., Celik G., Oc B., et al. Renal effects of coronary artery bypass graft surgery in diabetic and non-diabetic patients: a study with urinary neutrophil gelatinase-associated lipocalin and serum cystatin C. Kidney Blood Press Res. 2015; 40 (2): 141–52. https://doi.org/10.1159/000368490.

Chen S., Shi J.S., Yibulayin X., et al. Cystatin C is a moderate predictor of acute kidney injury in the early stage of traumatic hemorrhagic shock. Exp Ther Med. 2015; 10 (1): 237–40. https://doi.org/10.3892/etm.2015.2446.

Tung Y.C., Chang C.H., Chen Y.C., Chu P.H. Combined biomarker analysis for risk of acute kidney injury in patients with ST-segment elevation myocardial infarction. PLoS One. 2015; 10 (4): e0125282. https://doi.org/10.1371/journal.pone.0125282.

Yim H., Kym D., Seo D.K., et al. Serum cystatin C and microalbuminuria in burn patients with acute kidney injury. Eur J Clin Invest. 2015; 45 (6): 594–600. https://doi.org/10.1111/eci.12452.

Chen J., Lin J., Lin C. Serum and urinary biomarkers for predicting acute kidney injury after partial nephrectomy. Clin Invest Med. 2015; 38 (3): E82–9. https://doi.org/10.25011/cim.v38i3.22703.

Liu Y.J., Sun H.D., Chen J., et al. Klotho: a novel and early biomarker of acute kidney injury after cardiac valve replacement surgery in adults. Int J Clinical Exp Med. 2015; 8 (5): 7351–8.

Peng L., Wong K., Chio S., et al. Diagnostic value of cystatin C in contrast-induced acute kidney injury after percutaneous coronary intervention. Zhonghua Nei Ke Za Zhi. 2015; 54 (3): 188–92 (in Chinese).

Gong M., Yang Y., Zhang S. Value of acute renal injury associated biomarkers for patients in intensive care unit. Zhong Тan Вa Xue Xue Bao. Yi Xue Ban. 2015; 40 (10): 1083–8. https://doi.org/10.11817/j.issn.1672-7347.2015.10.005.

Gaygısız Ü., Aydoğdu M., Badoğlu M., et al. Can admission serum cystatin C level be an early marker subclinical acute kidney injury in critical care patients? Scand J Clin Lab Invest. 2016; 76 (2): 143–50. https://doi.org/10.3109/00365513.2015.1126854.

Mårtensson J., Jonsson N., Glassford N.J., et al. Plasma endostatin may improve acute kidney injury risk prediction in critically ill patients. Ann Intensive Care. 2016; 6: 6. https://doi.org/10.1186/s13613-016-0108-x.

Wang M., Zhang L., Yue R., et al. Significance of cystatin C for early diagnosis of contrast-induced nephropathy in patients undergoing coronary angiography. Med Sci Monit. 2016; 22: 2956–61. https://doi.org/10.12659/MSM.897241.

Choudhary A., Basu S., Dey S.K., et al. Association and prognostic value of serum cystatin C, IL-18 and uric acid in urological patients with acute kidney injury. Clin Chim Acta. 2018; 482: 144–8. https://doi.org/10.1016/j.cca.2018.04.005.

Abdelsalam M., Elmorsy E., Abdelwahab H., et al. Urinary biomarkers for early detection of platinum based drugs induced nephrotoxicity. BMC Nephrol. 2018; 19 (1): 219. https://doi.org/10.1186/s12882-018-1022-2.

Hasslacher J., Barbieri F., Harler U., et al. Acute kidney injury and mild therapeutic hypothermia in patients after cardiopulmonary resuscitation – a post hoc analysis of a prospective observational trial. Crit Care. 2018; 22: 154. https://doi.org/10.1186/s13054-018-2061-6.

Maiwall R., Kumar A., Bhardwaj A., et al. Cystatin C predicts acute kidney injury and mortality in cirrhotics: a prospective cohort study. Liver Int. 2018; 38 (4): 654–64. https://doi.org/10.1111/liv.13600.

Chai X., Huang H.B., Feng G., et al. Baseline serum cystatin C is a potential predictor for acute kidney injury in patients with acute pancreatitis. Dis Markers. 2018; 2018: 8431219. https://doi.org/10.1155/2018/8431219.

Lei L., Li L.P., Zeng Z., et al. Value of urinary KIM-1 and NGAL combined with serum Cys C for predicting acute kidney injury secondary to decompensated cirrhosis. Sci Rep. 2018; 8 (1): 7962. https://doi.org/10.1038/s41598-018-26226-6.

Neyra J.A., Hu M.C., Minhajuddin A., et al. Kidney tubular damage and functional biomarkers in acute kidney injury following cardiac surgery. Kidney Int Rep. 2019; 4 (8): 1131–42. https://doi.org/10.1016/j.ekir.2019.05.005.

Che M., Wang X., Xie B., et al. Use of both serum cystatin C and creatinine as diagnostic criteria for cardiac surgery-associated acute kidney injury and its correlation with long-term major adverse events. Kidney Blood Press Res. 2019; 44 (3): 415–25. https://doi.org/10.1159/000499647.

Jaques D.A., Spahr L., Berra G., et al. Biomarkers for acute kidney injury in decompensated cirrhosis: a prospective study. Nephrology. 2019; 24 (2): 170–80. https://doi.org/10.1111/nep.13226.

Насонова С.Н., Жиров И.В., Ледяхова М.В. и др. Ранняя диагностика острого почечного повреждения у пациентов с острой декомпенсацией хронической сердечной недостаточности. Терапевтический архив. 2019; 91 (4): 67–73. https://doi.org/10.26442/00403660.2019.04.000168.

Nasonova S.N., Zhirov I.V., Ledyakhova M.V., et al. Early diagnosis of acute renal injury in patients with acute decompensation of chronic heart failure. Therapeutic Archive. 2019; 91 (4): 67–73 (in Russ.). https://doi.org/10.26442/00403660.2019.04.000168.

Kim T.H., Lee H.A., Seo Y.S., et al. Assessment and prediction of acute kidney injury in patients with decompensated cirrhosis with serum cystatin C and urine N-acetyl-β-D-glucosaminidase. J Gastroenterol Hepatol. 2019; 34 (1): 234–40. https://doi.org/10.1111/jgh.14387.

Kararmaz A., Arslantas M.K., Aksu U., et al. Evaluation of acute kidney injury with oxidative stress biomarkers and Renal Resistive Index after cardiac surgery. Acta Chir Belg. 2021; 121 (3): 189–97. https://doi.org/10.1080/00015458.2019.1702371.

Pei Y., Chen W., Mao X., Zhu J. Serum cystatin C, Klotho, and neutrophil gelatinase-associated lipocalin in the risk prediction of acute kidney injury after acute myocardial infarction. Cardiorenal Med. 2020; 10 (6): 374–81. https://doi.org/10.1159/000507387.

Zong Q., Ge M., Chen T., et al. Risk factors and long-term outcomes of acute kidney injury complication after type A acute aortic dissection surgery in young patients. J Cardiothorac Surg. 2020; 15 (1): 315. https://doi.org/10.1186/s13019-020-01365-y.

Wang X., Lin X., Xie B., et al. Early serum cystatin C-enhanced risk prediction for acute kidney injury post cardiac surgery: a prospective, observational, cohort study. Biomarkers. 2020; 25 (1): 20–6. https://doi.org/10.1080/1354750X.2019.1688865.

Chen D., Cao C., Jiang L., et al. Serum cystatin C: a potential predictor for hospital-acquired acute kidney injury in patients with acute exacerbation of COPD. Chron Respir Dis. 2020; 17: 147997312094067. https://doi.org/10.1177/1479973120940677.

Wajda J., Dumnicka P., Sporek M., et al. Does beta-trace protein (BTP) outperform cystatin C as a diagnostic marker of acute kidney injury complicating the early phase of acute pancreatitis? J Clinical Med. 2020; 9 (1): 205. https://doi.org/10.3390/jcm9010205.

Hansson M., Gustafsson R., Jacquet C., et al. Cystatin C and α-1- microglobulin predict severe acute kidney injury in patients with hemorrhagic fever with renal syndrome. Pathogens. 2020; 9 (8): 666. https://doi.org/10.3390/pathogens9080666.

Budano C., Andreis A., De Filippo O., et al. A single cystatin C determination before coronary angiography can predict short and longterm adverse events. Int J Cardiol. 2020; 300: 73–9. https://doi.org/10.1016/j.ijcard.2019.09.069.

Nei A.M., Kashani K.B., Dierkhising R., Barreto E.F. Predictors of augmented renal clearance in a heterogeneous ICU population as defined by creatinine and cystatin C. Nephron. 2020; 144 (7): 313–20. https://doi.org/10.1159/000507255.

Chagan-Yasutan H., Hanan F., Niki T., et al. Plasma osteopontin levels is associated with biochemical markers of kidney injury in patients with leptospirosis. Diagnostics. 2020; 10 (7): 439. https://doi.org/10.3390/diagnostics10070439.

Магомедалиев М.О., Корабельников Д.И., Хорошилов С.Е. Прогностическое значение цистатина-С как предиктора развития острого повреждения почек при COVID-19. Общая реаниматология. 2023; 19 (2): 14–22. https://doi.org/10.15360/1813-9779-2023-2-2243.

Magomedaliev M.O., Korabelnikov D.I., Khoroshilov S.E. The predictive value of cystatin C for AKI in patients with COVID-19. General Reanimatology. 2023; 19 (2): 14–22 (in Russ.). https://doi.org/10.15360/1813-9779-2023-2-2243.

Bellomo R., Ronco C., Kellum J.A., et al. Acute renal failure – definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care. 2004; 8 (4): R204–12. https://doi.org/10.1186/cc2872.

Mehta R.L., Kellum J.A., Shah S.V., et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007; 11 (2): R31. https://doi.org/10.1186/cc5713.

Kidney Disease: Improving Global Outcomes (KDIGO). Acute Kidney Injury Work Group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012; 2 (1): 1–126. https://doi.org/10.1038/kisup.2012.2.

Магомедалиев М.О., Корабельников Д.И., Хорошилов С.Е. Острое повреждение почек при пневмонии. Российский медико-социальный журнал. 2019; 1 (1): 59–73. https://doi.org/10.35571/RMSJ.2019.1.006.

Magomedaliev M.O., Korabelnikov D.I., Khoroshilov S.Е. Acute kidney injury in patients with pneumonia. Russian Medical and Social Journal. 2019; 1 (1): 59–73 (in Russ.). https://doi.org/10.35571/RMSJ.2019.1.006.

Магомедалиев М.О., Корабельников Д.И., Хорошилов С.Е. Острое повреждение почек при тяжелом течении пневмоний, ассоциированных с новой коронавирусной инфекцией (COVID-19). Вестник Российской Военно-медицинской академии. 2022; 24 (3): 511– 20. https://doi.org/10.17816/brmma109938.

Magomedaliev M.O., Korabelnikov D.I., Khoroshilov S.E. Acute kidney injury in severe pneumonia associated with COVID-19. Bulletin of the Russian Military Medical Academy. 2022; 24 (3): 511–20 (in Russ.). https://doi.org/10.17816/brmma109938.

Kellum J.A., Sileanu F.E., Bihorac A., et al. Recovery after acute kidney injury. Am J Respir Crit Care Med. 2017; 195 (6): 784–91. https://doi.org/10.1164/rccm.201604-0799OC.

Корабельников М.О., Коновалов П.П., Магомедалиев М.О., Хорошилов С.Е. Клинико-эпидемиологическая характеристика острого повреждения почек при тяжелой внебольничной пневмонии у лиц молодого возраста. Военно-медицинский журнал. 2022; 343 (12): 38–45. https://doi.org/10.52424/00269050_2022_343_12_38.

Korabelnikov D.I., Konovalov P.P., Magomedaliev M.O., Khoroshilov S.E. Clinical and epidemiologicalcharacteristics of acute renal irritation in case of severe community-acquired pneumonia in young people. Military Medical Journal. 2022; 343 (12): 38–45 (in Russ.). https://doi.org/10.52424/00269050_2022_343_12_38.

Chertow G.M., Burdick E., Honour M., et al. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol. 2005; 16 (11): 3365–70. https://doi.org/10.1681/ASN.2004090740.

Parikh C.R., Abraham E., Ancukiewicz M., Edelstein C.L. Urine IL-18 is an early diagnostic marker for acute kidney injury and predicts mortality in the intensive care unit. J Am Soc Nephrol. 2005; 16 (10): 3046–52. https://doi.org/10.1681/ASN.2005030236.

Nejat M., Pickering J.W., Walker R.J., et al. Urinary cystatin C is diagnostic of acute kidney injury and sepsis, and predicts mortality in the intensive care unit. Crit Care. 2010; 14 (3): R85. https://doi.org/10.1186/cc9014.

Murray P.T., Mehta R.L., Shaw A., et al. Potential use of biomarkers in acute kidney injury: report and summary of recommendations from the 10th Acute Dialysis Quality Initiative consensus conference. Kidney Int. 2014; 85 (3): 513–21. https://doi.org/10.1038/ki.2013.374.

Kellum J.A., Sileanu F.E., Murugan R., et al. Classifying AKI by urine output versus serum creatinine level. J Am Soc Nephrol. 2015; 26 (9): 2231–8. https://doi.org/10.1681/ASN.2014070724.

Grubb A. Diagnostic value of analysis of cystatin C and protein HC in biological fluids. Clin Nephrol. 1992; 38 (Suppl. 1): S20–7.

Abrahamson M., Alvarez-Fernandez M., Nathanson C.M. Cystatins. Biochem Soc Symp. 2003; 70: 179–99. https://doi.org/10.1042/bss0700179.

Hall A., Håkansson K., Mason R.W., et al. Structural basis for the biological specificity of cystatin C. J Biol Chem. 1995; 270 (10): 5115– 21. https://doi.org/10.1074/jbc.270.10.5115.

Rawlings N.D., Barrett A.J. Evolution of proteins of the cystatin superfamily. J Mol Evol. 1990; 30 (1): 60–71. https://doi.org/10.1007/BF02102453.

Brown W.M., Dziegielewska K.M. Friends and relations of the cystatin superfamily-new members and their evolution. Protein Sci. 1997; 6 (1): 5–12. https://doi.org/10.1002/pro.5560060102.

Löfberg H., Grubb A.O. Quantitation of γ-trace in human biological fluids: Indications for production in the central nervous system. Scand J Clin Lab Invest. 1979; 39 (7): 619–26. https://doi.org/10.3109/00365517909108866.

Levey A., Inker L. Assessment of glomerular filtration rate in health and disease: a state of the art review. Clin Pharmacol Ther. 2017; 102 (3): 405–19. https://doi.org/10.1002/cpt.729.

Laterza O.F., Price C.P., Scott M.G. Cystatin C: an improved estimator of glomerular filtration rate? Clin Chem. 2002; 48 (5): 699–707.

Dharnidharka V.R., Kwon C., Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis. 2002; 40 (2): 221–6. https://doi.org/10.1053/ajkd.2002.34487.

Roos J.F., Doust J., Tett S.E., Kirkpatrick C.M.J. Diagnostic accuracy of cystatin C compared to serum creatinine for the estimation of renal dysfunction in adults and children – a meta-analysis. Clin Biochem. 2007; 40 (5–6): 383–91. https://doi.org/10.1016/j.clinbiochem.2006.10.026.

Croda-Todd M.T., Soto-Montano X.J., Hernández-Cancino P.A., Juárez-Aguilar E. Adult cystatin C reference intervals determined by nephelometric immunoassay. Clin Biochem. 2007; 40 (13–14): 1084–7. https://doi.org/10.1016/j.clinbiochem.2007.05.011.

Köttgen A., Selvin E., Stevens L.A., et al. Serum cystatin C in the United States: the Third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis. 2008; 51 (3): 385–94. https://doi.org/10.1053/j.ajkd.2007.11.019.

Gharaibeh K.A., Hamadah A.M., El-Zoghby Z.M., et al. Cystatin C predicts renal recovery earlier than creatinine among patients with acute kidney injury. Kidney Int Rep. 2018; 3 (2): 337–42. https://doi.org/10.1016/j.ekir.2017.10.012.

Digvijay K., Neri M., Fan W., et al. International survey on the management of acute kidney injury and continuous renal replacement therapies: year 2018. Blood Purif. 2019; 47 (1–3): 113–9. https://doi.org/10.1159/000493724.

Yong Z., Pei X., Zhu B., et al. Predictive value of serum cystatin C for acute kidney injury in adults: a meta-analysis of prospective cohort trials. Sci Rep. 2017; 7 (1): 41012. https://doi.org/10.1038/srep41012.

Zhang W., Zhang T., Ding D., et al. Use of both serum cystatin C and creatinine as diagnostic criteria for contrast-induced acute kidney injury and its clinical implications. J Am Heart Assoc. 2017; 6 (1): e004747. https://doi.org/10.1161/JAHA.116.004747.

Mandelbaum T., Scott D.J., Lee J., et al. Outcome of critically ill patients with acute kidney injury using the Acute Kidney Injury Network criteria. Crit Care Med. 2011; 39 (12): 2659–64. https://doi.org/10.1097/CCM.0b013e3182281f1b.

Fuchs L., Lee J., Novack V., et al. Severity of acute kidney injury and two-year outcomes in critically ill patients. Chest. 2013; 144 (3): 866– 75. https://doi.org/10.1378/chest.12-2967.

Hoste E.A.J., Bagshaw S.M., Bellomo R., et al. Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study. Int Care Med. 2015; 41 (8): 1411–23. https://doi.org/10.1007/s00134-015-3934-7.

Fortrie G., de Geus H.R.H., Betjes M.G.H. The aftermath of acute kidney injury: a narrative review of long-term mortality and renal function. Crit Care. 2019; 23 (1): 24. https://doi.org/10.1186/s13054-019-2314-z.

Kim C.S., Bae E.H., Ma S.K., Kim S.W. A prospective observational study on the predictive value of serum cystatin C for successful weaning from continuous renal replacement therapy. Kidney Blood Pres Res. 2018; 43 (3): 872–81. https://doi.org/10.1159/000490335.

Jung C.Y., Joo Y.S., Kim H.W., et al. Creatinine–cystatin C ratio and mortality in patients receiving intensive care and continuous kidney replacement therapy: a retrospective cohort study. Am J Kidney Dis. 2020; 77 (4): 509–16e1. https://doi.org/10.1053/j.ajkd.2020.08.014.

Ravn B., Prowle J.R., Mårtensson J., et al. Superiority of serum cystatin C over creatinine in prediction of long-term prognosis at discharge from ICU. Crit Care Med. 2017; 45 (9): e932–40. https://doi.org/10.1097/CCM.0000000000002537.

Willey J.Z., Moon Y.P., Husain S.A., et al. Creatinine versus cystatin C for renal function-based mortality prediction in an elderly cohort: the Northern Manhattan Study. PLoS One. 2020; 15 (1): e0226509. https://doi.org/10.1371/journal.pone.0226509.

Yang T., Sun S., Zhao Y., et al. Biomarkers upon discontinuation of renal replacement therapy predict 60-day survival and renal recovery in critically ill patients with acute kidney injury. Hemodial Int. 2018; 22 (1): 56–65. https://doi.org/10.1111/hdi.12532.

McIlroy D.R., Farkas D., Pan K., et al. Combining novel renal injury markers with delta serum creatinine early after cardiac surgery and riskstratification for serious adverse outcomes: an exploratory analysis. J Cardiothorac Vasc Anesth. 2018; 32 (5): 2190–200. https://doi.org/10.1053/j.jvca.2017.12.052.

The authors declare that there are no conflicts of interest present.